papaverine

P1, N=62, Completed, Huashan Hospital Affiliated to Fudan University; Huashan Hospital Affiliated to Fudan University

P4, N=110, Not yet recruiting, Western Galilee Hospital-Nahariya

P=N/A, N=126, Not yet recruiting, Western Galilee Hospital-Nahariya

P=N/A, N=144, Recruiting, Subei people's Hospital; Subei people's Hospital | Not yet recruiting --> Recruiting

Overall, these findings show papaverine could protect against cisplatin kidney damage without reducing its cytotoxic activity. Further research would allow the transition of these results to clinical practice.

The protective effects of papaverine may be attributed to the activation of FXR signaling pathways. These findings revealed that papaverine protects against ANIT-induced Cholestasis.

P1, N=28, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024

P1, N=24, Suspended, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2023 --> Dec 2024 | Recruiting --> Suspended | Trial primary completion date: Dec 2022 --> Dec 2024

P=N/A, N=1000, Recruiting, Johannes Gutenberg University Mainz

Microarray analysis shows higher apoptosis protein levels in the combination therapy group. In conclusion, this study demonstrated the role of papaverine in enhancing the antitumor activity of NDV, suggesting a promising strategy for breast cancer therapy through nonchemotherapeutic drugs.

EPROI provides 3D high-resolution pO quantification; EPR is better suited than DRS to characterize tumor hypoxia. PPV did not radiosensitize E0771 tumors nor p53/MCA sarcomas, which may be related to the complex pattern of vasculature in each tumor. Additionally, understanding model-dependent tumor hypoxia will provide a much-needed foundation for future therapeutic studies with hypoxic radiosensitizers.

In our experience, in line with the literature, we use a pure PPV without excipients 60 mg/2 ml diluted in 20 cc of 0,9% saline solution (0,3%) to prevent Hearing Loss during Posterior Fossa Microvascular Decompression for Typical Trigeminal Neuralgia and other cranial nerves potentially involved during VS and other CPA tumor resection. The aim of this commentary is to analyze and discuss the role of diluted intracisternal PPV for microvascular protection of cranial nerves during CPA tumor surgery.

Based on potentially druggable genes that we identified, palbociclib, sirolimus, and tacrolimus were under clinical trial for ALL. Additionally, chlorprothixene, sirolimus, dihydroergocristine, papaverine, and tamoxifen are the top five drug repositioning candidates for ALL according to the CMap score with dasatinib as a comparator. In conclusion, this study determines the practicability and the potential of integrated genomic network analysis in driving drug discovery in ALL.

More insight into the effects of the compound on cellular and molecular mechanisms is needed. Understanding the effects PPV may exert on tumorigenic cells may better researchers' understanding of phytomedicines and the effects of PPV and PPV-derived compounds in cancer.

We examined confounding by (1) indication, (2) dose, (3) age at report submission, (4) region, (5) stimulated reporting before and after 2014 when there was a sharp increase in awareness about the topic, (6) another phosphodiesterase type-5 inhibitor (tadalafil), (7) drugs prescribed for erectile dysfunction with different mechanisms of action (prostaglandin E1, testosterone, and papaverine), (8) drugs unrelated to erectile dysfunction but prescribed among the same age group (tamsulosin, metoprolol, and metformin), and (9) drugs associated with non-melanoma skin cancer (irbesartan and valsartan). Herein, we found that phosphodiesterase type-5 inhibitors prescribed for erectile dysfunction are associated with cutaneous and ocular melanoma. While there may be confounding by age, region, dose, and stimulated reporting, our results support the need to keep sildenafil on the Food and Drug Administration's list of drugs with potential signals of serious risks.

P1, N=28, Recruiting, Ohio State University Comprehensive Cancer Center | Not yet recruiting --> Recruiting